Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum (Q44153140)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 August 2010

Language	Label	Description	Also known as
English	Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum	scientific article published on 4 August 2010

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum (English)

1 reference

Europe PubMed Central

30 November 2017

phase I clinical trial

0 references

Plasmodium falciparum

0 references

0 references

malaria vaccine

1 reference

based on heuristic

inferred from title

1

object named as

Blaise Genton

1 reference

Europe PubMed Central

30 November 2017

Robert Sauerwein

10

object named as

Robert Sauerwein

1 reference

Europe PubMed Central

30 November 2017

Cornelus C Hermsen

6

object named as

Cornelus Hermsen

1 reference

Europe PubMed Central

30 November 2017

author name string

Valérie D'Acremont

2

1 reference

Europe PubMed Central

30 November 2017

Floriana Lurati-Ruiz

3

1 reference

Europe PubMed Central

30 November 2017

Daniele Verhage

4

1 reference

Europe PubMed Central

30 November 2017

Régine Audran

5

1 reference

Europe PubMed Central

30 November 2017

Liselotte Wolters

7

1 reference

Europe PubMed Central

30 November 2017

Christophe Reymond

8

1 reference

Europe PubMed Central

30 November 2017

François Spertini

9

1 reference

Europe PubMed Central

30 November 2017

language of work or name

0 references

publication date

4 August 2010

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

28

1 reference

Europe PubMed Central

30 November 2017

6573-6580

1 reference

Europe PubMed Central

30 November 2017

40

1 reference

Europe PubMed Central

30 November 2017

Malaria vaccines: a toy for travelers or a tool for eradication?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Malaria vaccines and their potential role in the elimination of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Pre-erythrocytic stage malaria vaccines: time for a change in path

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Pre-erythrocytic malaria vaccines: towards greater efficacy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Peptide based malaria vaccine development: personal considerations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

The dog that did not bark: malaria vaccines without antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.067

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.07.067

1 reference

Europe PubMed Central

30 November 2017

release_qwcpesfclrhulk3l2tjpg5p3si

1 reference

https://api.fatcat.wiki/v0/release/qwcpesfclrhulk3l2tjpg5p3si

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44153140&oldid=2107208215"